commercialization & tech transfer task force meeting, feb. 27, 2013
DESCRIPTION
Commercialization & Tech Transfer Task Force Meeting, Feb. 27, 2013TRANSCRIPT
![Page 1: Commercialization & Tech Transfer Task Force Meeting, Feb. 27, 2013](https://reader033.vdocuments.mx/reader033/viewer/2022061222/54c1404b4a795947678b45eb/html5/thumbnails/1.jpg)
COMMERCIALIZATION AND TECHNOLOGY TRANSFERTASK FORCE MEETINGFebruary 27, 2013 | 10 a.m. to 2 p.m.
LSU Shreveport | Noel Library 3rd Floor Assembly Room
![Page 2: Commercialization & Tech Transfer Task Force Meeting, Feb. 27, 2013](https://reader033.vdocuments.mx/reader033/viewer/2022061222/54c1404b4a795947678b45eb/html5/thumbnails/2.jpg)
Bill Silvia and Bill Comegys, Operations and TechnologySub-Committee Co-Chairs
WELCOME, CHARGE AND INTRODUCTIONS
![Page 3: Commercialization & Tech Transfer Task Force Meeting, Feb. 27, 2013](https://reader033.vdocuments.mx/reader033/viewer/2022061222/54c1404b4a795947678b45eb/html5/thumbnails/3.jpg)
Dr. Christel Slaughter, SSA Consultants
AGENDA REVIEWAND LOGISTICS
![Page 4: Commercialization & Tech Transfer Task Force Meeting, Feb. 27, 2013](https://reader033.vdocuments.mx/reader033/viewer/2022061222/54c1404b4a795947678b45eb/html5/thumbnails/4.jpg)
4
Meeting Information
This meeting is streaming live at:
www.lsushreveport.adobeconnect.com/lsu2015/
For more information about this task force or the Transition Advisory Team visit:
www.lsu.edu/lsu2015
![Page 5: Commercialization & Tech Transfer Task Force Meeting, Feb. 27, 2013](https://reader033.vdocuments.mx/reader033/viewer/2022061222/54c1404b4a795947678b45eb/html5/thumbnails/5.jpg)
Save the Date
Next Meeting:
March 13, 10 a.m. to noon LSU Ag Center, 214 Efferson Hall, Baton Rouge
![Page 6: Commercialization & Tech Transfer Task Force Meeting, Feb. 27, 2013](https://reader033.vdocuments.mx/reader033/viewer/2022061222/54c1404b4a795947678b45eb/html5/thumbnails/6.jpg)
6
Today’s Agenda
Introduction of the Presenter “Technology Transfer: A Report”
Margaret Dahl, Associate Provost for Economic Development and Director, Georgia BioBusiness Center
Lunch Joe Lovett, Managing General Partner, Louisiana Fund I Ross Barrett, Managing Partner, BVM Capital, LLC Dr. Tammy Dugas, LSUHSC-S, Department of Pharmacology,
Toxicology and Neuroscience Public Comment Adjournment
![Page 7: Commercialization & Tech Transfer Task Force Meeting, Feb. 27, 2013](https://reader033.vdocuments.mx/reader033/viewer/2022061222/54c1404b4a795947678b45eb/html5/thumbnails/7.jpg)
Bill Silvia, Operations and Technology Sub-Committee Co-Chair
INTRODUCTION OF THE PRESENTER
![Page 8: Commercialization & Tech Transfer Task Force Meeting, Feb. 27, 2013](https://reader033.vdocuments.mx/reader033/viewer/2022061222/54c1404b4a795947678b45eb/html5/thumbnails/8.jpg)
Margaret Wagner Dahl, Associate Provost for Economic Development and Director, Georgia BioBusiness Center
TECHNOLOGY TRANSFER: A REPORT
![Page 9: Commercialization & Tech Transfer Task Force Meeting, Feb. 27, 2013](https://reader033.vdocuments.mx/reader033/viewer/2022061222/54c1404b4a795947678b45eb/html5/thumbnails/9.jpg)
PROPOSAL REVIEW AND DISCUSSION:
THE HUMAN HEALTH TECHNOLOGY
COMMERCIALIZATION PROPOSAL
Facilitated by Margaret Wagner Dahl, Associate Provost for
Economic Development
University of Georgia
![Page 10: Commercialization & Tech Transfer Task Force Meeting, Feb. 27, 2013](https://reader033.vdocuments.mx/reader033/viewer/2022061222/54c1404b4a795947678b45eb/html5/thumbnails/10.jpg)
ORIGINAL INTENTION
The goal: improve processes to have better outcomes in technology-based economic development in the biomedical industry sector and build industry capacity in Louisiana
(Previous leadership specifically mandated the initiative focus on LSU’s biomedical research enterprise through three specific institutions-LSU New Orleans, LSU Shreveport and LSU Pennington)
![Page 11: Commercialization & Tech Transfer Task Force Meeting, Feb. 27, 2013](https://reader033.vdocuments.mx/reader033/viewer/2022061222/54c1404b4a795947678b45eb/html5/thumbnails/11.jpg)
PROPOSAL DEVELOPMENT PROCESS
21st Century health will be largely affected by the development of preventive and predictive medicine, biotechnology, molecular biology, and population health
Combined research enterprise represents over $135M per year, over $85M NIH funding-a respectable portfolio for commercialization opportunities
Models considered were derived from Georgia (Georgia Research Alliance); Seattle, Washington; Austin, Texas
Participants included in this process were formal and informal leaders comprising a wide constituency of professional economic developers, venture capitalists, business leaders and entrepreneurs as well as university senior administrators and faculty.
![Page 12: Commercialization & Tech Transfer Task Force Meeting, Feb. 27, 2013](https://reader033.vdocuments.mx/reader033/viewer/2022061222/54c1404b4a795947678b45eb/html5/thumbnails/12.jpg)
HUMAN HEALTH PILOT PROJECT GOALS
Play a strategic role in technology-based economic development by providing a robust set of activities to increase economic output from LSU-derived research in human health
Increase industry sponsored research Increase revenues from intellectual property Accelerate commercialization efforts to provide specific
resources to support and sustain spin-off companies under “proof of concept” activities
![Page 13: Commercialization & Tech Transfer Task Force Meeting, Feb. 27, 2013](https://reader033.vdocuments.mx/reader033/viewer/2022061222/54c1404b4a795947678b45eb/html5/thumbnails/13.jpg)
SUMMARY OF INITIATIVE ELEMENTS: THE ECOSYSTEM
Governance structure to provide general leadership and fiscal policy decisions (Chancellors from LSU Shreveport and New Orleans, Executive Director of Pennington)
Identify experienced personnel in deal-making, relationship building skills, and team-based decision making who will be dedicated to this specific project across the three institutions
Utilize a shared information platform with standardized operation procedures (enabling shared IP information, bundling technologies capabilities, contract management etc.)
![Page 14: Commercialization & Tech Transfer Task Force Meeting, Feb. 27, 2013](https://reader033.vdocuments.mx/reader033/viewer/2022061222/54c1404b4a795947678b45eb/html5/thumbnails/14.jpg)
THE ECOSYSTEM CONTINUED
Shared triage system for developing appropriate commercialization strategies
Shared marketing platform Establish a Proof of Concept Center approach including
grant funded startup Leverage established business community networks Partner with award winning technology based incubator
programs Ensure core lab infrastructure is readily accessible and
very affordable
![Page 15: Commercialization & Tech Transfer Task Force Meeting, Feb. 27, 2013](https://reader033.vdocuments.mx/reader033/viewer/2022061222/54c1404b4a795947678b45eb/html5/thumbnails/15.jpg)
RECOMMENDATIONS SUMMARY
“Unlike Detroit, there’s no caste system here. Our people don’t think about which executive they work for, just which project they are working on.” Rick Lepley, Senior VP, Mitsubishi – create The Team
Ensure the success of the Team by streamlining processes (expert patent counsel engagement, ability to negotiate terms, establish express template agreements where appropriate, signature authority by President, and measure satisfaction of faculty and business)
Establish CATALYST and partner with economic development professionals and acceleration/incubator organizations linked to localized angel networks and venture capital
![Page 16: Commercialization & Tech Transfer Task Force Meeting, Feb. 27, 2013](https://reader033.vdocuments.mx/reader033/viewer/2022061222/54c1404b4a795947678b45eb/html5/thumbnails/16.jpg)
SOME SPECIFIC AREAS FOR DISCUSSION:CATALYST CONCEPT
![Page 17: Commercialization & Tech Transfer Task Force Meeting, Feb. 27, 2013](https://reader033.vdocuments.mx/reader033/viewer/2022061222/54c1404b4a795947678b45eb/html5/thumbnails/17.jpg)
EXTERNAL EXAMPLE: GEORGIA’S VENTURELAB
Since 2002 Georgia through the Georgia Research Alliance VentureLab program has evaluated more than 600 inventions or discoveries at UGA, Georgia Tech, Emory, Georgia State, Morehouse, MCG, Clarke Atlanta
VentureLab grants were awarded to the most promising which has led to 120 early stage startups
They employee 600 people They have attracted $460M in private equity investment UGA VL: FY12 28 VL companies received external funding
($3.2M SBIR, industry, EPA) 4 moved into incubator
![Page 18: Commercialization & Tech Transfer Task Force Meeting, Feb. 27, 2013](https://reader033.vdocuments.mx/reader033/viewer/2022061222/54c1404b4a795947678b45eb/html5/thumbnails/18.jpg)
CONCLUSIONTHE RETURN ON INVESTMENT
Multiple standards of benchmarking necessary
- fostering the academic commercialization culture
- service, service, and more service
- cultivating academic entrepreneurship
Tangible 3 year measures:
- 130 cumulative invention disclosures
- 15 cumulative licenses
- revenues associated with upfront fees, milestone payments
- 6 startups (SBIR funding, angel investment, proof of concept)
- $1M industry sponsored research funding
![Page 19: Commercialization & Tech Transfer Task Force Meeting, Feb. 27, 2013](https://reader033.vdocuments.mx/reader033/viewer/2022061222/54c1404b4a795947678b45eb/html5/thumbnails/19.jpg)
OBSERVATIONS
Creating a culture of collaboration across institutions is extremely hard. By establishing a team dedicated to one goal: impacting human health through excellent commercialization of LSU research much would be achieved.
This is important because it is a key measure of how engaged LSU is in economic development
APLU: national discussion occurring regarding the role of the Land Grant in economic development-LSU needs to be at the table
![Page 20: Commercialization & Tech Transfer Task Force Meeting, Feb. 27, 2013](https://reader033.vdocuments.mx/reader033/viewer/2022061222/54c1404b4a795947678b45eb/html5/thumbnails/20.jpg)
CONCLUSIONS
Teaching a faculty member to be an entrepreneur is like teaching a cat to swim:It can be done.You will lose blood.You’ll never be satisfied with the results.You will annoy the cat.
Good Luck!
![Page 21: Commercialization & Tech Transfer Task Force Meeting, Feb. 27, 2013](https://reader033.vdocuments.mx/reader033/viewer/2022061222/54c1404b4a795947678b45eb/html5/thumbnails/21.jpg)
Group Discussion
LUNCH
![Page 22: Commercialization & Tech Transfer Task Force Meeting, Feb. 27, 2013](https://reader033.vdocuments.mx/reader033/viewer/2022061222/54c1404b4a795947678b45eb/html5/thumbnails/22.jpg)
Managing General Partner, Louisiana Fund I
JOE LOVETT
![Page 23: Commercialization & Tech Transfer Task Force Meeting, Feb. 27, 2013](https://reader033.vdocuments.mx/reader033/viewer/2022061222/54c1404b4a795947678b45eb/html5/thumbnails/23.jpg)
Managing Partner, BVM Capital, LLC
ROSS BARRETT
![Page 24: Commercialization & Tech Transfer Task Force Meeting, Feb. 27, 2013](https://reader033.vdocuments.mx/reader033/viewer/2022061222/54c1404b4a795947678b45eb/html5/thumbnails/24.jpg)
BVM Capital Overview for LSU Transition
Sub-Committee
Technology and Commercialization
February 2013
by
Ross P. Barrett
![Page 25: Commercialization & Tech Transfer Task Force Meeting, Feb. 27, 2013](https://reader033.vdocuments.mx/reader033/viewer/2022061222/54c1404b4a795947678b45eb/html5/thumbnails/25.jpg)
25
Management Team Russell O. Vernon, Founding Partner,
based in New York; former President of Commerce Capital Markets, Inc.; Director of Investment Operations at Warburg Pincus; and Director of Operations at Chancellor Capital Asset Management; U.S. Military Academy, BS; U.S. Army War College, MSS (Strategic Studies); Columbia University, MBA.
Ross P. Barrett, Founding Managing Partner, based in Shreveport, LA; co-founder of VC Experts, Inc.; former legislative aide to U.S. Senator J. Bennett Johnston; SMU, BS; LSU Law School, JD; NYU School of Law, LLM in Taxation. Member, Louisiana Committee of 100.
![Page 26: Commercialization & Tech Transfer Task Force Meeting, Feb. 27, 2013](https://reader033.vdocuments.mx/reader033/viewer/2022061222/54c1404b4a795947678b45eb/html5/thumbnails/26.jpg)
Portfolio Companies-Louisiana Ventures, LP
26
![Page 27: Commercialization & Tech Transfer Task Force Meeting, Feb. 27, 2013](https://reader033.vdocuments.mx/reader033/viewer/2022061222/54c1404b4a795947678b45eb/html5/thumbnails/27.jpg)
Portfolio Companies—Themelios Ventures, LP
2727
![Page 28: Commercialization & Tech Transfer Task Force Meeting, Feb. 27, 2013](https://reader033.vdocuments.mx/reader033/viewer/2022061222/54c1404b4a795947678b45eb/html5/thumbnails/28.jpg)
Themelios--Capital Invested as of December 31, 2011 (plus syndicated capital).
The economic impact of Venture Capital--syndicate, federal and state capital leverage
Themelios Ventures, LP invested capital
Capital Invested Additional Capital Syndicated
Company $651,892.00 $350,000.00
Company $689,936.00 $1,900,000.00
Company $668,506.76 $5,169,137.24
Company $3,000,000.00 $18,369,000.00
Company $775,000.00 $1,100,000.00
Company $1,222,500.00 $8,000,000.00
Company . $1,011,875.00 $1,300,000.00
Total $8,019,709.76 $36,188,137
28
![Page 29: Commercialization & Tech Transfer Task Force Meeting, Feb. 27, 2013](https://reader033.vdocuments.mx/reader033/viewer/2022061222/54c1404b4a795947678b45eb/html5/thumbnails/29.jpg)
Capital Invested as of December 31, 2011 (syndicated plus Federal and State Grants)
Multiplier Effect of Leveraged Capital is 6.7X
The economic impact of Venture Capital--syndicate, federal and state capital leverage
Themelios Ventures, LP invested capital
Capital Invested Additional Capital Syndicated Federal State Total
Company . $651,892.00 $350,000.00 $- $125,000.00
Company $689,936.00 $1,900,000.00 $- $-
Company $668,506.76 $5,169,137.24 $4,144,000.00 $180,729.00
Company $3,000,000.00 $18,369,000.00 $800,000.00 $800,000.00
Company $775,000.00 $1,100,000.00 $- $-
Company $1,222,500.00 $8,000,000.00 $2,000,000.00 $-
Company . $1,011,875.00 $1,300,000.00 $1,700,000.00 $350,000.00
Total $8,019,709.76 $36,188,137 $8,644,000.00 $1,455,729 $54,307,576.00
29
![Page 30: Commercialization & Tech Transfer Task Force Meeting, Feb. 27, 2013](https://reader033.vdocuments.mx/reader033/viewer/2022061222/54c1404b4a795947678b45eb/html5/thumbnails/30.jpg)
Institutional Co-Investors: Life Science
BioAdvance - Philadelphia, PA
Ben Franklin Ventures -Philadelphia, PA
Maple Leaf, LP (Baton Rouge)
Sanofi-Aventis (Paris)
Trident Capital—Palo Alto, CA
Louisiana Fund I - Baton Rouge
Research Corporation Technologies, (RCT) - Tucson, AZ
Long Branch Ventures (New Orleans)
Taraval Associates - Menlo Park, CA
Tech Coast Angels - Los Angeles, LA
30
![Page 31: Commercialization & Tech Transfer Task Force Meeting, Feb. 27, 2013](https://reader033.vdocuments.mx/reader033/viewer/2022061222/54c1404b4a795947678b45eb/html5/thumbnails/31.jpg)
Our Investments—Two example of What We Have Created
31
![Page 32: Commercialization & Tech Transfer Task Force Meeting, Feb. 27, 2013](https://reader033.vdocuments.mx/reader033/viewer/2022061222/54c1404b4a795947678b45eb/html5/thumbnails/32.jpg)
32
Esperance Pharmaceuticals, Inc.
Overview: Lytic peptide research that has cancer killing effects.
Status:- Closed over $21,000,000 Series A, A-1 and B financing transaction.- Licensed technology from LSU; --Currently FDA trials at Mayo Clinic, MD Anderson, etc. - Comparable sales from $200-800mm.
![Page 33: Commercialization & Tech Transfer Task Force Meeting, Feb. 27, 2013](https://reader033.vdocuments.mx/reader033/viewer/2022061222/54c1404b4a795947678b45eb/html5/thumbnails/33.jpg)
33
Esperance Pharmaceuticals, Inc.
History of Company:• Pennington and Ag Center showed
collaboration.• Due Diligence by investors• Themelios syndicated with two other groups
(LFI and RCT)• Seed Round: $750,000 in 2006-2007• Series A Round: $9mm in 2008-2010; Series A-1
Round: $4.5mm; Series B Round: $8.0mm from Sanofi-Aventis (May 2011)
• Result: over $20mm invested based on LSU Research.
![Page 34: Commercialization & Tech Transfer Task Force Meeting, Feb. 27, 2013](https://reader033.vdocuments.mx/reader033/viewer/2022061222/54c1404b4a795947678b45eb/html5/thumbnails/34.jpg)
34
Embera NeuroTherapeutics, Inc.
Overview: Addiction therapy drug development company based in Louisiana.
Update: - Original human data secured in 2009- 45 cocaine addicted patients in a double-blinded, placebo controlled study. -Smoking Cessation study at Pennington in 2013
![Page 35: Commercialization & Tech Transfer Task Force Meeting, Feb. 27, 2013](https://reader033.vdocuments.mx/reader033/viewer/2022061222/54c1404b4a795947678b45eb/html5/thumbnails/35.jpg)
35
Overall Important Points
Live in an era of less (ex: Postal Service versus UPS/FedEx) Intangibles and Reputation Critically important because ROI is hard
to justify Increase Volume, Volume, Volume: not everything will work. Depends on policies and procedures that are certain and clear Clear Guidelines on who can negotiate what Accountability and Leadership Inefficiencies with Process of negotiation Make it easy
![Page 36: Commercialization & Tech Transfer Task Force Meeting, Feb. 27, 2013](https://reader033.vdocuments.mx/reader033/viewer/2022061222/54c1404b4a795947678b45eb/html5/thumbnails/36.jpg)
LSUHSC-S, Department of Pharmacology, Toxicology and Neuroscience
DR. TAMMY DUGAS
![Page 37: Commercialization & Tech Transfer Task Force Meeting, Feb. 27, 2013](https://reader033.vdocuments.mx/reader033/viewer/2022061222/54c1404b4a795947678b45eb/html5/thumbnails/37.jpg)
Technology Transfer: The Faculty Perspective
Dr. Tammy R. Dugas, Ph.D.Associate Professor of Pharmacology,
Toxicology and NeuroscienceLSU Health Sciences Center -
Shreveport
![Page 38: Commercialization & Tech Transfer Task Force Meeting, Feb. 27, 2013](https://reader033.vdocuments.mx/reader033/viewer/2022061222/54c1404b4a795947678b45eb/html5/thumbnails/38.jpg)
Tech transfer and commercialization = foreign language for many faculty
Faculty are not trained for this.
Tech transfer and commercialization is often not considered a scholarly activity Tenure and promotion is a peer-
reviewed process Without a global acceptance of tech
transfer activities, the effort may seem ill-advised.
Faculty are often not aware that they may have something that might be marketable.
![Page 39: Commercialization & Tech Transfer Task Force Meeting, Feb. 27, 2013](https://reader033.vdocuments.mx/reader033/viewer/2022061222/54c1404b4a795947678b45eb/html5/thumbnails/39.jpg)
And then along came the solution:
The LSUHSC-S happened upon Dr. Tony Giordano, Assistant Dean for Research and Business Development Both scientist and expert in business
development He attended faculty/student seminars Sought out faculty individually Formed research interest groups Helped faculty conceive of ideas, submit
patents and form companies
![Page 40: Commercialization & Tech Transfer Task Force Meeting, Feb. 27, 2013](https://reader033.vdocuments.mx/reader033/viewer/2022061222/54c1404b4a795947678b45eb/html5/thumbnails/40.jpg)
And then along came a solution:
The LSUHSC-S happened upon Dr. Tony Giordano, Assistant Dean for Research and Business Development Both scientist and expert in business
development He attended faculty/student seminars Sought out faculty individually Formed research interest groups Helped faculty conceive of ideas, submit
patents and form companiesThere is a need for a scientist/advocate on the campus!
![Page 41: Commercialization & Tech Transfer Task Force Meeting, Feb. 27, 2013](https://reader033.vdocuments.mx/reader033/viewer/2022061222/54c1404b4a795947678b45eb/html5/thumbnails/41.jpg)
2012 LSUHSC-S Research Planning Retreat
Faculty driven 60 faculty 6 committees Proposed recommendations were compiled,
debated and ranked 3 committees submitted recommendations
for a new TT office at the LSUHSC-S (see handout).
The recommendations were combined into one final recommendation.
Ranked 4th of 24 total recommendations put forth by the faculty
![Page 42: Commercialization & Tech Transfer Task Force Meeting, Feb. 27, 2013](https://reader033.vdocuments.mx/reader033/viewer/2022061222/54c1404b4a795947678b45eb/html5/thumbnails/42.jpg)
The final recommendation:
Two positions are necessary: Floor-walker – scientist Business Development
In at least one proposal, the faculty conceded that the foundation may have a role in spearheading/financing at least part of the effort. E.g., Business development expertise
could be placed there, as long as the individual worked pro-actively for the good of institutional research.
![Page 43: Commercialization & Tech Transfer Task Force Meeting, Feb. 27, 2013](https://reader033.vdocuments.mx/reader033/viewer/2022061222/54c1404b4a795947678b45eb/html5/thumbnails/43.jpg)
Examples the faculty discussed:
University of Minnesota’s Medical Devices Center Innovation Fellows Program 4 mid-level careers
professionals/year. Program provides mentoring
on starting a company. The professionals work with
scientists and physicians to decide what products are needed.
Goal: 20-30 inventions patented/year.
Each professional spins out their best idea.
Program partners the fellows with VC groups specializing in medical devices.
![Page 44: Commercialization & Tech Transfer Task Force Meeting, Feb. 27, 2013](https://reader033.vdocuments.mx/reader033/viewer/2022061222/54c1404b4a795947678b45eb/html5/thumbnails/44.jpg)
Partners with universities in the Cleveland area
Facilitates business formation and recruitment to grow health care companies and to commercialize technologies in Cleveland.
They report: > 170 companies created, recruited,
accelerated > $1.5 billion in new funding attracted by
their company partners >$210 million in revenues collected by
technology offices >540 TT deals with industry partners
![Page 45: Commercialization & Tech Transfer Task Force Meeting, Feb. 27, 2013](https://reader033.vdocuments.mx/reader033/viewer/2022061222/54c1404b4a795947678b45eb/html5/thumbnails/45.jpg)
The faculty need advocates!
Advocates on the campus Important for mentoring Identifying technologies that are
marketable Giving the faculty a sense of security
Who advocates for faculty in licensing and other negotiations?
System level = risk management Risk = reward?!
![Page 46: Commercialization & Tech Transfer Task Force Meeting, Feb. 27, 2013](https://reader033.vdocuments.mx/reader033/viewer/2022061222/54c1404b4a795947678b45eb/html5/thumbnails/46.jpg)
Group Discussion
PUBLIC COMMENTS
![Page 47: Commercialization & Tech Transfer Task Force Meeting, Feb. 27, 2013](https://reader033.vdocuments.mx/reader033/viewer/2022061222/54c1404b4a795947678b45eb/html5/thumbnails/47.jpg)
ADJOURNMENT